BioCryst Pharma (BCRX) Tops Q2 EPS by 1c; Sees Increase in Net Operating Cash
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.74 -0.71%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $5.44 million.
Based upon current trends and assumptions, as well as the Company’s planned operations, BioCryst expects net operating cash use to be in the range of $37 to $43 million, reflecting an increase of $5 million from previous projections, and its total operating expenses to be in the range of $57 to $69 million, unchanged from previous projections.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Based upon current trends and assumptions, as well as the Company’s planned operations, BioCryst expects net operating cash use to be in the range of $37 to $43 million, reflecting an increase of $5 million from previous projections, and its total operating expenses to be in the range of $57 to $69 million, unchanged from previous projections.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
- Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
